Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double‐blinded, placebo‐controlled trial
-
- Junko Takahashi
- Noah Animal Hospital 3‐4‐15 Joto Kofu Yamanashi 400‐0861 Japan
-
- Satoko Kanda
- Vet Derm Tokyo Dermatological and Laboratory Service for Animals 910 Shoubusawa Fujisawa‐shi Kanagawa 252‐0823 Japan
-
- Ichiro Imanishi
- Department of Microbiology Kitasato University School of Medicine 1‐15‐1 Kitasato, Minami‐ku Sagamihara Kanagawa 252‐0374 Japan
-
- Tadashi Hisano
- Smile Animal Hospital 3‐22‐21 Maebaranishi Funabashi Chiba 274‐0825 Japan
-
- Teruyasu Fukamachi
- Smile Animal Hospital 3‐22‐21 Maebaranishi Funabashi Chiba 274‐0825 Japan
-
- Norihito Taguchi
- Mori Animal Hospital 7‐5‐34 Gokou Matsudo Chiba 270‐2213 Japan
-
- Shoko Momiyama
- Nunokawa Animal Hospital 273 Shimokurata‐cho Yokohama Kanagawa 244‐0815 Japan
-
- Satoshi Nishiyama
- Nishiyama Animal Hospital 1‐10‐1 Miyazono Nagareyama Chiba 270‐0155 Japan
-
- Tomoki Motegi
- Veterinary Medical Center Graduate School of Agriculture and Life Sciences The University of Tokyo 1‐1‐1 Yayoi, Bunkyo‐ku Tokyo 113‐8657 Japan
-
- Keita Iyori
- Vet Derm Tokyo Dermatological and Laboratory Service for Animals 910 Shoubusawa Fujisawa‐shi Kanagawa 252‐0823 Japan
この論文をさがす
説明
<jats:sec><jats:title>Background</jats:title><jats:p>Oclacitinib is an effective systemic therapy for dogs with atopic dermatitis (AD). Few studies have evaluated concurrent topical treatment with oclacitinib in dogs.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To evaluate the efficacy and safety of combination therapy of oclacitinib and 0.0584% hydrocortisone aceponate (HCA) spray in dogs with AD.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>Eighteen dogs with AD.</jats:p></jats:sec><jats:sec><jats:title>Methods and materials</jats:title><jats:p>This study was a randomized, double‐blinded, placebo‐controlled trial. All dogs were treated with oclacitinib (0.4–0.6 mg/kg twice daily for 14 days, then once daily for 14 days) and randomized to receive either HCA spray or placebo spray, applied once daily for seven days then every other day through to Day (D)28. Clinical assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4<jats:sup>th</jats:sup> iteration (CADESI‐4) and the pruritus Visual Analog Scale (PVAS) every seven days, and blood and urine tests every 14 days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The mean CADESI‐4 and PVAS scores were significantly reduced on D7 and D14 compared to D0 in both groups (<jats:italic>P</jats:italic> < 0.05). From D14 to D21, CADESI‐4 and PVAS scores were significantly increased in the placebo group (<jats:italic>P</jats:italic> < 0.005), and not in the HCA‐treated group. The mean reduction from baseline of the HCA‐treated group was significantly higher than that of the placebo group for the PVAS and CADESI‐4 on D21 (59.9% versus 27.6%, <jats:italic>P</jats:italic> = 0.0216) and D28 (56.0% versus 30.5%, <jats:italic>P</jats:italic> = 0.0109), respectively. One dog in the HCA‐treated group was withdrawn as a consequence of developing diarrhoea.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Topical application of 0.0584% HCA spray may be useful for preventing exacerbation of pruritus and clinical lesions when tapering oclacitinib therapy in dogs with AD.</jats:p></jats:sec>
収録刊行物
-
- Veterinary Dermatology
-
Veterinary Dermatology 32 (2), 119-, 2020-11-13
Wiley